PESG Research releases a new market update on Silexion Therapeutics (NASDAQ: SLXN). Silexion recently announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback